Alvotech Acquires Ivers-Lee Group to Boost Packaging and Assembly Capabilities in Europe

Alvotech Acquires Ivers-Lee Group

Alvotech, a leading biopharmaceutical company specializing in manufacturing biosimilar medicines, announced its acquisition of Ivers-Lee Group to expand its assembly and packaging capacities in Europe. Ivers Lee is a leading company in Switzerland, which works on assembly and high-quality packaging in the pharmaceutical sector. The acquisition won’t affect Ivers-Lee’s legal entity, but the operations will be included under Alvotech’s operations.

The founder, CEO, and chairman of Alvotech, Robert Wessman, on the acquisition,

“Ivers-Lee has been an Alvotech preferred partner in assembly and packaging for several years. We know and trust each other very well, having worked closely together. As Alvotech prepares for the launch of three new biosimilars in 2025 and sales growth in global markets, the integration of Ivers-Lee into our Technical Operations provides added flexibility and capacity to meet increased global demand for our biosimilars, maintaining the highest level of quality and service.”

The Ivers-Lee group also has its operational business unit at Lorrach, Germany, which was originally founded in Burgdorf, Switzerland, in 1947. The Alvotech acquisition won’t change the managing director, Peter Schupbach. He will join the technical operations senior leadership team of Alvotech.

The managing director of Ivers-Lee expressed his views by saying that Alvotech offers financial strength for developing more opportunities in the market. He also mentions the acquisition as a sign of stability for the company and its employees.

The Burgdorf site of Ivers-Lee is approved by the FDA and also licensed by GMP, which has enabled it to attract international consumers. The company will keep on providing CMO services to its existing clients.

Alvotech’s developments include nine disclosed biosimilar candidates, which aim to treat autoimmune disorders, osteoporosis, respiratory disease, cancer, and eye disorders. They have formed a commercial partnership network to provide global reach and leverage local expertise in Japan, China, the United States, and some countries in the Middle East and South America.